2,598 reports of this reaction
1.3% of all OLANZAPINE reports
#20 most reported adverse reaction
NEUROLEPTIC MALIGNANT SYNDROME is the #20 most commonly reported adverse reaction for OLANZAPINE, manufactured by Eli Lilly and Company. There are 2,598 FDA adverse event reports linking OLANZAPINE to NEUROLEPTIC MALIGNANT SYNDROME. This represents approximately 1.3% of all 204,278 adverse event reports for this drug.
OLANZAPINE has an overall safety score of 88 out of 100. Patients taking OLANZAPINE who experience neuroleptic malignant syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROLEPTIC MALIGNANT SYNDROME is a less commonly reported adverse event for OLANZAPINE, but still significant enough to appear in the safety profile.
In addition to neuroleptic malignant syndrome, the following adverse reactions have been reported for OLANZAPINE:
The following drugs have also been linked to neuroleptic malignant syndrome in FDA adverse event reports:
NEUROLEPTIC MALIGNANT SYNDROME has been reported as an adverse event in 2,598 FDA reports for OLANZAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROLEPTIC MALIGNANT SYNDROME accounts for approximately 1.3% of all adverse event reports for OLANZAPINE, making it a notable side effect.
If you experience neuroleptic malignant syndrome while taking OLANZAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.